SCHEMBL6404380

SCHEMBL6404380

O=C(Cc1cccc(O)c1)c1c(O)cccc1P(=O)(O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTBP2 P56545 1/20 0.42
LMNA P02545 1/20 0.40
BCL2L1 Q07817 2/20 0.38
ENPP2 Q13822 1/20 0.38
PIK3CA P42336 2/20 0.37
MEN1 O00255 2/20 0.37
MAPT P10636 2/20 0.37
HPGD P15428 2/20 0.37
KMT2A Q03164 2/20 0.37
CYP3A4 P08684 1/20 0.37
MAPK1 P28482 1/20 0.37
ALPG P10696 1/20 0.37
PTK2B Q14289 1/20 0.37
HIF1A Q16665 1/20 0.36
ALOX5 P09917 1/20 0.36
GAA P10253 1/20 0.36
BCL2 P10415 1/20 0.36
MCL1 Q07820 1/20 0.36
DRD2 P14416 1/20 0.36
DRD1 P21728 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6396398 0.87 LMNA (0.49) CTBP2LMNABCL2L1ENPP2PIK3CA
SCHEMBL6399719 0.86 SLC5A1 (0.48) LMNAMEN1MAPTHPGDKMT2A
SCHEMBL6396182 0.85 ACHE (0.46) LMNAPIK3CAMEN1MAPTHPGD
SCHEMBL6403060 0.84 ACHE (0.50) MEN1MAPTKMT2AGAADRD2
SCHEMBL6403464 0.80 INPPL1 (0.41) CTBP2LMNAMEN1MAPTHPGD
SCHEMBL6404374 0.80 LMNA (0.41) CTBP2LMNAENPP2PIK3CAMEN1
SCHEMBL6396972 0.78 ESR1 (0.46) CTBP2LMNAENPP2PIK3CAMEN1
SCHEMBL6396068 0.78 CTBP2 (0.43) CTBP2LMNAENPP2PIK3CAMEN1
SCHEMBL27697248 0.77 MAPT (0.60) CTBP2LMNAENPP2PIK3CAMEN1
SCHEMBL16671845 0.75 AKR1B1 (0.50) CTBP2LMNABCL2L1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 CTBP2 1783/4885LMNA 4647/4885BCL2L1 4261/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 CTBP2 1802/4885LMNA 4664/4885BCL2L1 4199/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 CTBP2 1783/4885LMNA 4647/4885BCL2L1 4261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.